Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin and Brilique for prevention of tumour cell-induced platelet aggregation
2014-004049-29Phase 2Completed
- Sponsor
- University of Leicester
- Start
- Apr 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ticagrelor and aspirin in Non-hematologic malignancy (3 arms), sponsored by University of Leicester. Primary endpoint: Differential effect of aspirin vs Brilique (ticagrelor) on tumour cell-platelet interactions. Started Apr 2015; status: completed.
02
Drugs
ticagreloraspirin
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2014-004049-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004049-29.